Systematic review ID | ||||||
---|---|---|---|---|---|---|
Brindle 200631 | Sheridan 200832 | Sheridan 201033 | Waldron 201134 | van Dieren 201235 | Usher-Smith 201536 | |
Review objective(s) | ‘To determine the accuracy of assessing CVD risk in the primary prevention of CVD and its impact on clinical outcomes’ | ‘To assess whether global CHD risk scores result in clinical benefits or harms’ | ‘To assess the effect of providing global CHD risk information to adults’ | ‘To compare different interventions used to communicate cardiovascular risk and assess their impact on patient related outcomes’ | ‘To review the primary prevention studies that focused on the development, validation and impact assessment of a cardiovascular risk model, scores or rules’ | ‘To systematically review whether the provision of information on cardiovascular disease (CVD) risk to healthcare professionals and patients impacts their decision-making, behaviour and ultimately patient health.’ |
Population | People ‘predominantly free from symptomatic CVD’ | ‘Adults (>18) with no prior history of CVD’ | ‘Adults with no history of CVD’ | Adults (>18) | ‘People with type 2 diabetes’ | People ‘with no history of CVD’ |
Intervention(s) | ‘Healthcare professional using a CVD risk score to aid primary prevention’ | ‘Physician knowledge of a global CHD risk score’ | ‘Global CHD risk presentation as the primary intervention or part of a multipart intervention’ | ‘Communication interventions (of any format) for individualised CVD assessment’ | ‘CVD predictions models that have been developed… or validated in a diabetes population’ | ‘Intervention strategy consisted of provision of a CVD risk model estimate to either physicians or patients’ |
Comparison(s) | Usual care | ‘Either simple risk factor counting or no formal assessment of risk’ | Not prespecified | Control or usual care arm | Not prespecified | No ‘provision of a CVD risk model estimate’ |
Country of primary review author | UK | United States of America | United States of America | UK | The Netherlands | UK |
AMSTAR | 4/11 | 4/11 | 7/11 | 5/11 | 0/11 | 5/11 |
Eligible study designs | RCTs | Any design | Any design | ‘Any quantitative design’ | Not specified | Randomised and non-randomised primary studies |
Databases searched | CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, ZETOC, ISI Proceedings | MEDLINE | MEDLINE, PsycINFO, CINAHL, Cochrane Database | ASSIA, CINAHL, EMBASE, MEDLINE, PsycINFO, Science Citation Index expanded | MEDLINE | MEDLINE, PubMed |
Date of database search | 2004 | 2007 | 2008 | 2008 | 2011 | 2013 |
Meta-analysis? | No | No | No | No | No | Yes |
Review method of quality assessment | No formal assessment. ‘Information on the methodological quality of the trials including the method of randomisation, concealment of allocation, baseline group comparisons and blind outcome assessment was collected’ | Criteria adapted from the US Preventive Services Task Force | Criteria adapted from the US Preventive Services Task Force | Downs and Black checklist | Quality not assessed | Followed critical appraisal skills programme guidelines |
Review authors' conclusions | ‘Evidence supporting the use of cardiovascular risk scores for primary prevention is scarce’ | ‘We found surprisingly little evidence that physician knowledge of global CHD risk currently translates into improved clinical outcomes’ | ‘Global CHD risk information seems to improve the accuracy of risk perception and may increase intent to initiate CHD prevention among individuals at moderate to high risk. The effect of global risk presentation on more distal outcomes is less clear and seems to be related to the intensity of accompanying interventions.’ | ‘Better quality trials are needed that compare different risk presentation formats before conclusions can be drawn’ | ‘The impact of applying these risk scores in clinical practice is almost completely unknown, but their use is recommended in various national guidelines.’ | ‘There seems evidence that providing CVD risk model estimates to professionals and patients improves perceived CVD risk and medical prescribing, with little evidence of harm on psychological well- being.’ |
CHD, coronary heart disease.